IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co ...

Alliance News 27 May, 2024 | 6:49AM
Email Form Facebook Twitter LinkedIn RSS

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

"Datopotamab deruxtecan is the only investigational therapy to show a clinically meaningful survival improvement in patients with previously treated nonsquamous non-small cell lung cancer versus docetaxel, which has long been unsurpassed in this post-targeted treatment and post-immunotherapy setting," says Susan Galbraith, executive vice president of oncology research & development at AstraZeneca.

"These results reinforce the potential for datopotamab deruxtecan to replace conventional chemotherapy in this late-line setting and underscore our confidence in ongoing trials evaluating this therapy in first-line lung cancer," she continues.

Dato-DXd was discovered by Daiichi Sankyo, and is being jointly-developed alongside AstraZeneca.

Current Daiichi stock price: up 3.4% at JPY5,627.00 each in Tokyo on Monday

12-month change: up 24%

Current Astra stock price: 12,296.00 pence, closed down 0.9% on Friday

12-month change: up 6.9%

By Elizabeth Winter, Alliance News senior correspondent

Comments and questions to

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
AstraZeneca PLC 12,364.00 GBX 0.19
Daiichi Sankyo Co Ltd 5,464.00 JPY 2.38

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures